BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  AstraZeneca, Argenx Score Phase III Wins in Autoimmune Space

  Two biologic therapeutic candidates have met their primary endpoints in phase III trials, including AstraZeneca’s Champion-NMOSD trial and Argenx’s Advance trial.

  May 5, 2022

   · 

  3 min read

   · 

  Jazmine Colatriano, M.S.
• 

  Research Roundup: COVID-19 Cognitive Impairment Equal to 20 Years of Aging

  Here’s a look at some of this week’s most interesting research news.

  May 5, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  Researchers Use CRISPR to Reset Anxiety, Alcohol Use Disorder

  Researchers at the University of Illinois at Chicago have uncovered the possibility of utilizing gene editing to reverse a cause of anxiety and alcohol use disorder (AUD).

  May 5, 2022

   · 

  3 min read

   · 

  Jazmine Colatriano, M.S.
• 

  Business

  BioCryst’s Orladeyo Launch Overshadowed by FDA Hold on PNH Asset

  BioCryst’s success of its Orladeyo launch in its Q1 report was overshadowed by the news that the FDA had placed a partial clinical hold on three of its clinical trials evaluating BCX9930

  May 5, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Amylyx Augments Case for ALS Drug Ahead of PDUFA Date

  A post hoc analysis of data from the Phase II CENTAUR study showed a 10.6-month longer median survival duration for AMX0035 participants, Amylyx announced Thursday.

  May 5, 2022

   · 

  5 min read

   · 

  Alex Keown
• 

  Drug Development

  AstraZeneca’s Heart Disease Drug Farxiga Delivers Key Endpoints in Phase III

  AstraZeneca’s proposed treatment for heart disease delivered positive high-level results from its Phase III DELIVER trial of Farxiga. Here’s more about this drug.

  May 5, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Intellia Previews Upcoming ATTR Readouts in Q1 Earnings Call

  Intellia’s first-quarter financial conference call and report focused on the ongoing Phase I trial of NTLA-2001 in transthyretin (ATTR) amyloidosis with polyneuropathy patients.

  May 5, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  CinCor’s Terry Coelho is Building Bridges Between Finance & Business Units

  For Terry Coelho, being CFO is about becoming a trusted strategic partner across the business. It’s about building bridges.

  May 5, 2022

   · 

  4 min read

   · 

  Gail Dutton
• 

  Policy

  FDA Refutes Pfizer CEO’s Recommendation of Second Paxlovid Round Upon Rebound

  The FDA’s reaction came after Pfizer CEO Albert Bourla said that physicians may give a second five-day course of Paxlovid if patients see a spike in their SARS-CoV-2 viral load.

  May 5, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Report: Porcine Virus May Have Killed Heart Transplant Patient

  New research indicates the heart that David Bennet received was infected with porcine cytomegalovirus, a virus that can cause respiratory and pregnancy complications in pigs.

  May 5, 2022

   · 

  2 min read

   · 

  Alex Keown